Related video above: New push to test COVID-19 vaccines in diverse groupsJohnson & Johnson’s COVID-19 vaccine candidate begins Phase 3 trials in the United States today. Trials for the single-dose vaccine will include up to 60,000 adult participants at nearly 215 sites in the U.S. and internationally.Phase 3 trials will begin immediately, with the first participants receiving doses on Wednesday, Johnson & Johnson Chief Scientific